InsidersTradesSigma
Total declarations
Companies
▲ Purchases (22 ops.)
▼ Sales (2 ops.)
Explore the full record of transactions filed by RA CAPITAL MANAGEMENT, L.P., Board Member. Officer active across 18 companies, notably Werewolf Therapeutics, Inc.. In total, 66 disclosures have been recorded. Total volume traded: €76.7m. The latest transaction was filed on 12 May 2026 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations66 total
€135,5186,387 shares@ €21.217850.0% of flow
Common Stock
SEC:0001231919-26-000495:0·
Ideal exit: 6 Feb 2027 (T+270)
€135,5186,387 shares@ €21.2178100.0% of flow
Common Stock
SEC:0001231919-26-000495·
Ideal exit: 6 Feb 2027 (T+270)
€2,291302 shares@ €7.58590.0014% mcap1.5% of flow
Common Stock
SEC:0001104659-22-073920:0·
Ideal exit: 18 Mar 2023 (T+270)
€19m9,480,052 shares@ €2.03850.61% mcap100.0% of flow
Ordinary Shares
SEC:0001104659-22-072990:0·
Ideal exit: 13 Mar 2023 (T+270)
€151,70220,000 shares@ €7.58510.094% mcap98.5% of flow
Common Stock
SEC:0001104659-22-071465:0·
Ideal exit: 10 Mar 2023 (T+270)
05,543 shares0
Common Stock
SEC:0001104659-22-071026:0·
04,500 shares0
Common Stock
SEC:0001104659-22-069745:0·
€340,6961,005,686 shares@ €0.33882.20% mcap30.9% of flow
Common Stock
SEC:0001104659-22-065351:0·
€760,6221,250,000 shares@ €0.60854.91% mcap69.1% of flow
Common Stock
SEC:0001104659-22-064706:0·
3,642,229 shares
Common Stock
SEC:0001104659-22-059645:0·
€31m2,200,000 shares@ €14.09316.41% mcap100.0% of flow
Common Stock
SEC:0001104659-22-052318:0·
Ideal exit: 21 Jan 2023 (T+270)
1,699,998 shares
Common Stock
SEC:0001104659-22-041080:0·
€722,778175,318 shares@ €4.1227100.0% of flow
Common Stock
SEC:0001104659-22-040146:0·
Ideal exit: 23 Dec 2022 (T+270)
€4m342,143 shares@ €11.29290.88% mcap32.1% of flow
Common Stock
SEC:0001104659-22-034568:0·
Ideal exit: 9 Dec 2022 (T+270)
€478,75040,154 shares@ €11.92290.11% mcap4.0% of flow
Common Stock
SEC:0001104659-22-032990:0·
Ideal exit: 4 Dec 2022 (T+270)
€747,48563,662 shares@ €11.74150.17% mcap6.2% of flow
Common Stock
SEC:0001104659-22-031596:0·
Ideal exit: 29 Nov 2022 (T+270)
€101,4498,746 shares@ €11.59940.023% mcap0.8% of flow
Common Stock
SEC:0001104659-22-029417:0·
Ideal exit: 25 Nov 2022 (T+270)
€3m214,922 shares@ €11.84090.58% mcap21.1% of flow
Common Stock
SEC:0001104659-22-027432:0·
Ideal exit: 20 Nov 2022 (T+270)
€2m166,229 shares@ €12.99520.49% mcap17.9% of flow
Common Stock
SEC:0001104659-22-025736:0·
Ideal exit: 14 Nov 2022 (T+270)
€2m166,229 shares@ €12.95220.49% mcap17.9% of flow
Common Stock
SEC:0001104659-22-024375:0·
Ideal exit: 11 Nov 2022 (T+270)
616,786 shares
Common Stock
SEC:0001567619-22-001163·
616,786 shares
Common Stock
SEC:0001567619-22-001163:0·
785,303 shares
Common Stock
SEC:0001567619-21-018789·
785,303 shares
Common Stock
SEC:0001567619-21-018789:0·
668,854 shares
Common Stock
SEC:0001567619-21-018355·
25 of 66 declarations
About RA CAPITAL MANAGEMENT, L.P.
RA Capital Management, L.P. is a multi-stage investment manager focused on building and backing healthcare and life science companies. In the context of its publicly traded U.S. portfolio companies — including 89bio, Janux Therapeutics, Acumen Pharmaceuticals, Werewolf Therapeutics, and Therapeutics Acquisition Corp. — the most notable role associated with RA Capital is that of long-term investor and board-level governance participant. Public company filings show that RA Capital professionals frequently serve as directors or investor-representatives, with active involvement in strategic oversight, capital allocation, and development planning. ([racap.com](https://www.racap.com/about-us/our-team?utm_source=openai)) RA Capital is widely known for its evidence-based investing approach and for combining scientific analysis with competitive-landscape research through its TechAtlas capability. The firm invests across private and public markets, supports company formation, and works with businesses from discovery through commercialization. That model is reflected in the companies linked to RA Capital, which are typically focused on innovative therapeutic areas such as oncology, neurodegeneration, rare disease, and next-generation biotechnology. ([racap.com](https://www.racap.com/about-us?utm_source=openai)) Notable public evidence of RA Capital’s activity includes financing support, board participation, and strategic engagement around clinical development and corporate growth. In multiple portfolio companies, RA Capital-linked directors have been part of decisions affecting governance, capital structure, and pipeline prioritization. Rather than a single operating executive role, RA Capital’s significance lies in its consistent board influence and its strategic support of emerging and public biotech companies in the United States market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1781174/000095017024048671/2024_proxy_statement.htm?utm_source=openai))
